Evaluating penicillin allergy clinical decision-making tools to enhance penicillin allergy delabeling
Authors:
Open Access
- 24 April 2026
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 5 (4) , 100719
Abstract
No abstract availableKeywords
Funding Information
- University of California, San Francisco
This publication has 11 references indexed in Scilit:
- Risk of Self-Reported Penicillin Allergy Despite Removal of Penicillin Allergy LabelJAMA Network Open, 2024
- Evaluating the PEN-FAST Clinical Decision-making Tool to Enhance Penicillin Allergy DelabelingJAMA Internal Medicine, 2023
- Risk-stratified management to remove low-risk penicillin allergy labels in the patients with COVID-19 in the intensive care unitThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care settingThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision ruleAnnals of Allergy, Asthma & Immunology, 2022
- Urticaria: The 1-1-1 Criterion for Optimized Risk Stratification in β-Lactam Allergy DelabelingThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Role of clinical history in beta-lactam hypersensitivityCurrent Opinion in Allergy and Clinical Immunology, 2021
- Development and Validation of a Penicillin Allergy Clinical Decision RuleJAMA Internal Medicine, 2020
- Identifying Low-Risk Beta-Lactam Allergy Patients in a UK Tertiary CentreThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Antibiotic allergyThe Lancet, 2019